427 results on '"Seo, Ho Kyung"'
Search Results
2. Lymphatic Embolization versus Sclerotherapy for Symptomatic Post-operative Pelvic Lymphocele (LESPOL): A Randomized Pilot Study
3. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
4. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
5. Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study
6. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
7. Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy
8. Evaluation of the Efficacy of Solifenacin for Preventing Catheter-Related Bladder Discomfort After Transurethral Resection of Bladder Tumors in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective, Randomized, Multicenter Study
9. Risk stratification and management of non‐muscle‐invasive bladder cancer: A physician survey in six Asia‐Pacific territories.
10. Controversies in terminology associated with management of BCG‐unresponsive NMIBC in Asia‐Pacific.
11. TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer : Stage-Matched Analysis of a Large Multicenter National Cohort
12. LBA03-08 PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
13. MP63-05 OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A
14. The Prognostic Impact of Angiolymphatic Invasion in Bladder Urothelial Carcinoma Patients Undergoing Radical Cystectomy
15. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
16. List of Contributors
17. Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis
18. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.
19. Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations
20. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study
21. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard, biomarkers and emerging strategies
22. Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients
23. Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea
24. Clinical Implication of Preoperative Renal Function on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy
25. The effect of predisposing atheroembolic risk factors on renal functional recovery between laparoscopy and open technique in patients with T1-stage renal cell carcinoma who underwent partial nephrectomy: a retrospective comparison study
26. Update of the Diagnostic and Therapeutic Role of the Pelvic Lymph Node Dissection Boundaries During Radical Cystectomy in Muscle Invasive Bladder Cancer
27. Enhanced Recovery After Surgery Program for Radical Cystectomy
28. Targeted Inhibition of O-Linked β-N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder
29. Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy
30. Additional file 1 of Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study
31. Haplotype Analysis of Prostate Stem Cell Antigen and Association With Prostate Cancer Risk
32. De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors
33. Lymphatic Embolization versus Sclerotherapy for Symptomatic Post-operative Pelvic Lymphocele (LESPOL): A Randomized Pilot Study
34. Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder
35. CONCENTRATION OF MITOMYCIN-C IN URINE ACCORDING TO URINE PH AFTER INTRAVESICAL INSTILLATION OF MITOMYCIN-C IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: MP13-04
36. Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy
37. Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
38. Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology
39. A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma
40. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment
41. MP40-17 INCIDENCE AND RISK FACTORS OF RECURRENCE AFTER HYDROCELE REPAIR IN CHILDREN
42. Incidental Prostate Cancer Detected by Cystoprostatectomy in Korean Men
43. Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer
44. Urologic complications of laparoscopic radical hysterectomy and lymphadenectomy
45. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract
46. Pelvic floor musculature and bladder neck changes before and after continence recovery after radical prostatectomy in pelvic MRI
47. IMPORTANCE OF THE THERAPEUTIC RESPONSIVENESS OF PRIMARY RENAL TUMOR ON FIRST CT EVALUATION FOR THE PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SIGNIFICANCE OF TUMOR SIZE, NECROSIS, HISTOLOGY AND CONTRAST-ENHANCING ATTENUATION: MP57-01
48. ANTITUMOR ACTIVITY OF C-MYC INHIBITOR KSI-3716 IN A GEMCITABINE-RESISTANT BLADDER CANCER: MP21-15
49. Intravesical Instillation of c-MYC Inhibitor KSI-3716 Suppresses Orthotopic Bladder Tumor Growth
50. The Prognosis and Oncological Predictor of Urachal Carcinoma of the Bladder: A Large Scale Multicenter Cohort Study Analyzed 203 Patients With Long Term Follow-Up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.